Loading…
Baird Medical Investment Holdings Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BDMD.
▼ -92.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.36 | $7.60 | $10.71 | $10.26 | |
| P/E | 20.9x | — | 13.3x | 21.0x | 20.9x |
| P/S | 6.4x | 1.9x | 5.2x | 10.0x | 7.5x |
| P/B | 6.9x | 1.3x | 4.9x | 8.8x | 10.2x |
| EPS | -$0.98 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HBIOHarvard Bioscience Inc | $7.92 | — | 4.9x | — | -89.95% | $36.05M |
| CNTXContext Therapeutics Inc. | $0.38 | — | 0.9x | — | -76.14% | $35.25M |
| ATYRaTYR PHARMA INC | $0.36 | — | 0.7x | — | -98.68% | $34.96M |
| RADXRadiopharm Theranostics Ltd | $2.41 |
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Company description provided by Yahoo Finance.
| $0.57 |
| $0.51 |
| $0.49 |
| Profit margin | 33.57% | -121.04% | 33.62% | 33.52% | 36.41% |
| ROE | 30.45% | -86.96% | 31.40% | 29.50% | 49.56% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.8x |
| — |
| -92.10% |
| $34.84M |
| COSMCosmos Health Inc. | $0.37 | — | 1.4x | — | -104.00% | $37.25M |
| QNCXQuince Therapeutics, Inc. | $33.75 | — | — | — | -153.84% | $34.33M |